Cipla (CIPLA) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue reached INR 6,957 crore, up 4% year-over-year, with EBITDA margin at 25.6% and profit after tax at INR 1,298 crore, reflecting 10.2% YoY growth.

• One India business crossed INR 3,000 crore in quarterly revenue for the first time, now representing 44% of global revenue and achieving its highest-ever Q1 sales.

• North America revenue was $226 million, with Albuterol leading the US MDI market at 19.5% share and new oncology launches.

• Africa and EMU businesses grew 11% and 8% YoY in USD terms, respectively, with South Africa private business growing 1.5x faster than the market.

• Unaudited consolidated and standalone financial results for the quarter ended 30th June 2025 were approved and released, with statutory auditors providing an unmodified review conclusion.

Financial highlights

• Gross margin improved by 156 bps YoY to 68.8% due to favorable product mix.

• Total expenses rose 8% YoY, mainly from employee increments and higher R&D spend (INR 432 crore, 6.2% of revenue).

• Net cash position remains strong with INR 10,379 crore and total debt at INR 459 crore as of June 30.

• Other income increased to INR 259 crore from INR 160 crore year-over-year.

• Equity increased to INR 32,665 crore from INR 28,058 crore year-over-year.

Outlook and guidance

• Maintains FY26 EBITDA margin guidance of 23.5%-24.5%.

• US business targets $1 billion sales by FY27, driven by pipeline launches including Symbicort and biosimilars.

• North America pipeline includes launches of biosimilars and differentiated respiratory assets, with 2-3 peptide assets expected in FY26.

• India business expected to grow in line with the industry for the next three quarters.

• Continued focus on innovative respiratory and chronic therapies in India, with strategic restructuring to drive triple therapy launches.